(Q36360341)

13 August 2017

1 reference

title

Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy (English)

1 reference

13 August 2017

1 reference

2

Antona J Wagstaff

1 reference

13 August 2017

Marit D Moen

1

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

65

1 reference

13 August 2017

issue

18

1 reference

13 August 2017

page(s)

2657-2674

1 reference

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200565180-00012

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200565180-00012

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200565180-00012

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200565180-00012

Secular trends in stroke incidence and mortality. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200565180-00012

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

21 January 2018

1 reference

12 December 2020

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

Inhibition of platelet aggregability by losartan in essential hypertension

1 reference

12 December 2020

Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure

1 reference

12 December 2020

Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan

1 reference

12 December 2020

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study

1 reference

12 December 2020

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

1 reference

12 December 2020

Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

1 reference

12 December 2020

Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study

1 reference

12 December 2020

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

1 reference

12 December 2020

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

12 December 2020

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

1 reference

12 December 2020

Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence

1 reference

12 December 2020

The LIFE study: the straw that should break the camel's back

1 reference

12 December 2020

Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling

1 reference

12 December 2020

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study

1 reference

12 December 2020

Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy

1 reference

12 December 2020

Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats

1 reference

12 December 2020

Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia

1 reference

12 December 2020

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group

1 reference

12 December 2020

Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy

1 reference

12 December 2020

International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention

1 reference

12 December 2020

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

1 reference

12 December 2020

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

12 December 2020

The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization

1 reference

12 December 2020

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

12 December 2020

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

12 December 2020

The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme

1 reference

12 December 2020

Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials

1 reference

12 December 2020

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

12 December 2020

Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy

1 reference

12 December 2020

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

1 reference

12 December 2020

Losartan: in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy

1 reference

12 December 2020

Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks

1 reference

12 December 2020

Atenolol in hypertension: is it a wise choice?

1 reference

12 December 2020

Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension

1 reference

12 December 2020

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

1 reference

12 December 2020

Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study

1 reference

12 December 2020

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

1 reference

12 December 2020

Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension

1 reference

12 December 2020

Effect of losartan on human platelet activation

1 reference

12 December 2020

Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective

1 reference

12 December 2020

Guidelines from the British Hypertension Society

1 reference

12 December 2020

Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension

1 reference

12 December 2020

Do angiotensin II antagonists provide benefits beyond blood pressure reduction?

1 reference

12 December 2020

Clinical pharmacokinetics of losartan

1 reference

12 December 2020

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial

1 reference

12 December 2020

Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study

1 reference

12 December 2020

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

12 December 2020

Prevention and treatment of stroke in patients with hypertension

1 reference

12 December 2020

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

1 reference

12 December 2020

Redefining efficacy of antihypertensive therapies beyond blood pressure reduction--the role of angiotensin II antagonists

1 reference

12 December 2020

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

12 December 2020

A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure

1 reference

12 December 2020

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

1 reference

12 December 2020

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

12 December 2020

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

12 December 2020

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

1 reference

12 December 2020

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

1 reference

12 December 2020

Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study

1 reference

12 December 2020

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

12 December 2020

Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries

1 reference

12 December 2020

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

1 reference

12 December 2020

10.2165/00003495-200565180-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1001270216

0 references

1 reference